Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LXEO 
Lexeo Therapeutics, Inc. Common Stock (LXEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LXEO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.38
1 Year Target Price $16.38
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.09% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 257.05M USD | Price to earnings Ratio - | 1Y Target Price 16.38 |
Price to earnings Ratio - | 1Y Target Price 16.38 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.45 - 11.77 | Updated Date 08/29/2025 |
52 Weeks Range 1.45 - 11.77 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.21 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.91 | Actual -0.6 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.91% | Return on Equity (TTM) -75.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 133065778 | Price to Sales(TTM) - |
Enterprise Value 133065778 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 416.34 | Enterprise Value to EBITDA -6.02 | Shares Outstanding 54001200 | Shares Floating 29378358 |
Shares Outstanding 54001200 | Shares Floating 29378358 | ||
Percent Insiders 0.45 | Percent Institutions 89.31 |
Upturn AI SWOT
Lexeo Therapeutics, Inc. Common Stock
Company Overview
History and Background
Lexeo Therapeutics, Inc. is a gene therapy company founded in 2021, focused on developing treatments for genetically defined cardiovascular and central nervous system diseases. The company is relatively new, and is in clinical stages to develop and deliver innovative AAV-based gene therapies.
Core Business Areas
- Cardiovascular Gene Therapies: Developing gene therapies for inherited cardiovascular diseases, such as dilated cardiomyopathy.
- Central Nervous System Gene Therapies: Developing gene therapies for neurological disorders, such as Alzheimer's disease and other neurodegenerative conditions.
Leadership and Structure
The leadership team includes R. Nolan Townsend (CEO), Jay Palescandolo (CFO), and various VPs overseeing research and development. The organizational structure is typical of a biotech company, with functional departments dedicated to research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- LX2006 (Friedreich's Ataxia Cardiomyopathy): LX2006 is an AAV-based gene therapy being developed for Friedreich's Ataxia Cardiomyopathy. Market share data is currently unavailable, as the product is in clinical trials. Competitors targeting similar genetic targets but using different modalities (e.g., small molecule drugs) exist, such as Larimar Therapeutics (LRMR).
- LX1001 (Alzheimer's Disease): LX1001 is an AAV-based gene therapy for Alzheimer's disease targeting APOE2. Market share data is not yet available, as the product is in clinical trials. Competitors include companies developing amyloid-beta targeting antibodies such as Biogen (BIIB) and Eli Lilly (LLY), although LX1001 has a different therapeutic mechanism.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing regulatory acceptance. It's characterized by high potential but also high risk, due to the complexities of gene delivery and potential for adverse events.
Positioning
Lexeo Therapeutics is positioned as a clinical-stage company focused on genetically defined cardiovascular and CNS diseases, utilizing AAV gene therapy. Its competitive advantage lies in its specific disease targets and AAV vector technology.
Total Addressable Market (TAM)
The total addressable market for gene therapies targeting cardiovascular and CNS diseases is estimated to be in the tens of billions of dollars. Lexeo is positioning itself to capture a portion of this market with its specific therapeutic programs. Specific market size for each individual disease target varies.
Upturn SWOT Analysis
Strengths
- Proprietary AAV gene therapy platform
- Strong focus on genetically defined diseases
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- Limited operating history
- Dependence on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
Opportunities
- Expanding pipeline through strategic partnerships
- Securing regulatory approvals for lead candidates
- Advancing gene therapy technology
- Addressing unmet medical needs in rare diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Adverse events associated with gene therapy
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- BLUE
- LRMR
Competitive Landscape
Lexeo faces competition from larger pharmaceutical companies with more established pipelines and resources. Its competitive advantage lies in its AAV gene therapy platform and specific disease targets.
Growth Trajectory and Initiatives
Historical Growth: N/A due to limited operating history.
Future Projections: Future growth depends on the success of its clinical trials and regulatory approvals. Analyst estimates suggest potential for significant growth if key milestones are met.
Recent Initiatives: Recent initiatives include advancing lead clinical programs (LX2006, LX1001) and expanding its pipeline through research and development.
Summary
Lexeo Therapeutics is an early-stage gene therapy company with a promising pipeline targeting genetically defined cardiovascular and CNS diseases. Its success hinges on positive clinical trial outcomes and regulatory approvals. It faces significant competition from larger, more established pharmaceutical companies. Lexeo needs to navigate the challenges of regulatory hurdles and potential adverse events, while continuing to develop its proprietary technology and expanding its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry news
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexeo Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-11-03 | CEO & Director Mr. R. Nolan Townsend | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.lexeotx.com |
Full time employees 61 | Website https://www.lexeotx.com | ||
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.